Publicacións nas que colabora con Josep Tabernero Caturla (12)

2023

  1. A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

    Biomedicine and Pharmacotherapy, Vol. 159

2022

  1. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

    European Journal of Cancer, Vol. 177, pp. 154-163

  2. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

    British Journal of Cancer, Vol. 126, Núm. 6, pp. 874-880

2021

  1. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis

    Cancer Chemotherapy and Pharmacology, Vol. 87, Núm. 1, pp. 113-124

  2. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

2019

  1. A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 121, Núm. 5, pp. 378-383

  2. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

    Annals of Oncology, Vol. 30, Núm. 3, pp. 439-446

2018

  1. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

    British Journal of Cancer, Vol. 119, Núm. 12, pp. 1464-1470

2017

  1. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: An expert taskforce review

    Annals of Oncology, Vol. 28, Núm. 12, pp. 2943-2949

  2. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

    European Journal of Cancer, Vol. 82, pp. 16-24

2016

  1. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

    The Lancet Oncology, Vol. 17, Núm. 10, pp. 1386-1395

2012

  1. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10